Jia Yueting’s FF responded: There will be no risk of delisting when submitting financial reports in a timely manner, and the expected losses in the third quarter will increase
Liankang Biotechnology Group (00690.HK): Bogutai? (Terripatide injection) application for marketing has been officially accepted by the State Food and Drug Administration
Zhitong Hong Kong stocks knew about it early︱ (December 16) US clean energy stocks and ETFs collectively rose, pay attention to the fluctuations in the stock prices of small metal sectors such as CITIC Damanganese (01091)